Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral
October 18, 2022 5:23 AM EDT
RBC Capital analyst Brian Abrahams downgraded NeuBase Therapeutics (NASDAQ: NBSE) from Outperform to Sector Perform with a price target of $1.00 (from $12.00).
The analyst comments "On Friday, NBSE announced a major restructuring as part of a cost-saving measure and we... More
October 14, 2022 4:05 PM EDT
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (NeuBase or the Company) today announced plans to restructure the Company to focus on the advancement of its platform in gene editing. Implementation of this strategy, which follows a strategic internal review by the Companys board of directors and management team, includes several initiatives aimed at streamlining the organization, reducing operating expenses, preserving capital, and creating long-term shareholder value.
After careful consideration of the current development timelines for our pipeline in conjunction with the tightening of the capital markets for small biotech companies over the past year,... More
